Aurinia Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Aurinia Pharmaceuticals

27/02/2025 14:32

Aurinia Pharmaceuticals Inc AUPH.OQ reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -19 cents.  The mean expectation of six analysts for the quarter was for a loss of 2 cents per share. Wall Street expected results to range from -9 cents to 16 cents per share.

Revenue rose 32.8% to $59.87 million from a year ago; analysts expected $59.94 million.

Aurinia Pharmaceuticals Inc's reported EPS for the quarter was 1 cent​.

The company reported quarterly net income of $1.43 million.

Aurinia Pharmaceuticals Inc shares had fallen by 11.5% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $10.93

This summary was machine generated from LSEG data February 27 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.02
0.01
Beat
Sep. 30 2024
0.02
0.10
Beat
Jun. 30 2024
0.01
0.01
Met
Mar. 31 2024
-0.14
-0.03
Beat